



Available Online through

www.ijptonline.com

DIFFERENT APPROACHES TO DESIGN AND EVALUATION OF COLON SPECIFIC DRUG DELIVERY SYSTEMS

Sateesh Kumar Vemula* and Prabhakar Reddy Veerareddy

St.Peter's Institute of Pharmaceutical Sciences, Vidyanagar, Hanamkonda.

E-Mail: *vemulasateesh15@gmail.com.*

Received On: 11-11-2009

Accepted On: 28-11-2009

ABSTRACT

Oral administration of different dosage forms is the most commonly used method due to greater flexibility in design of dosage form and high patient acceptance, but the gastrointestinal tract presents several formidable barriers to drug delivery. In oral colon-specific drug delivery system, colon has a large amount of lymphoma tissue (facilitates direct absorption in to the blood), negligible brush boarder membrane activity, and much less pancreatic enzymatic activity as compared with the small intestine. Colon-specific drug delivery has gained increased importance not just for the delivery of the drugs for treatment of local diseases associated with the colon but also for its potential for the delivery of proteins and therapeutic peptides. Different approaches are designed based on prodrug formulation, pH-sensitivity, time-dependency (lag time), microbial degradation and osmotic pressure etc to formulate the different dosage forms like tablets, capsules, multiparticulates, microspheres, liposomes for colon targeting. The efficiency of drug delivery system is evaluated using different in vitro and in vivo release studies. This review updated the research on different approaches for formulation and evaluation of colon-specific drug delivery systems (CDDS).

Keywords: Colon specific drug delivery system, Microbial degradation, Osmotic Pressure, pH-sensitivity, Prodrug, Time dependency.

INTRODUCTION

In the past two decades, the pharmaceutical scientists are extensively investigated in the area of colonic region for targeted drug delivery system. Targeted drug delivery to the colon is mainly for the treatment of colonic diseases, for drugs like proteins and peptides, for the treatment of diseases sensitive to circadian rhythms such as Asthma, Angina and Rheumatoid arthritis and for delivery of steroids, which absorbable in colon. The advent of slow release technologies increase the chances for a drug to be released in the colon and thus this organ has an important role to play in drug absorption from oral sustained release formulations.

In 1942, Svartz discovered that sulfasalazine; the sulfanilamide prodrug of 5-aminosalicylicacid (5-ASA) is effective in the treatment of rheumatoid arthritis and anti-inflammatory disease. The exact mode by which the drug target itself to the colon was elucidated much latter in 1970 i.e., colon specific azoreductase splits sulfasalazine causing the release of the active moiety 5-aminosalicylicacid. After the several other azo-bonds containing compounds designed to locally release 5-aminosalicylicacid were synthesized bensalazine, balsalazide and olsalazine. In1986, Saffron and coworkers described the use of azo containing acrylic polymers to the delivery of protein drugs like insulin to the colon (Girish et al. 2006).

Colon-specific drug delivery system offers the following therapeutic advantages (Girish et al. 2006, Chourasia et al. 2003, Sarasija et al. 2000, Vyas and Roop, 2006):

- Reducing the adverse effects in the treatment of colonic diseases (ulcerative colitis, colorectal cancer, crohn's disease etc.)
- By producing the 'friendlier' environment for peptides and proteins when compared to upper gastrointestinal tract.
- Minimizing extensive first pass metabolism of steroids.

- Preventing the gastric irritation produced by oral administration of NSAIDS.
- Delayed release of drugs to treat angina, asthma and rheumatoid arthritis.

To achieve successful colon targeting it should overcome the following limitations (Jack et al., 2006).

- The location at the distal portion of the alimentary canal, the colon is difficult to access.
- Successful delivery requires the drug to be in solution before it arrives in the colon, but the fluid content in the colon is lower and more viscous than in upper GIT, which is the limiting factor for poorly soluble drugs.
- Lower surface area and relative tightness of the tight junctions in the colon can restrict drug transport across the mucosa in to the systemic circulation.

ANATOMY AND PHYSIOLOGY OF COLON

Irrespective of therapy desired for local (colonic) or systemic delivery of drug, the development and aim of the drug delivery to colon remains same (Vyas and Roop, 2006), that is

- The drug must not absorb from other regions of the gastro intestinal tract (GIT).
- It should only suffer negligible degradation in the small intestine lumen.
- The release of the drug in the colon should be at quantitatively controlled rate and the released drug in the colon should be absorbed from the lumen of the large intestine without any appreciable degradation.

In order to meet these properties, a thorough knowledge of the anatomy and physiology of GIT is required. In GIT, large intestine starts from the ileocecal junction to the anus with a length of about 1.5 meters (adults) and is divided into three parts; they are colon, rectum and anal canal. The colon is the upper five feet of large intestine and mainly situated in the abdomen. The colon is a cylindrical tube lined by mucosa. The cecum, colon ascends, colon transversale, colon descendens and recto sigmoid colon made of the colon. Colon is made up of four-layers, serosa, muscularis externa, sub mucosa, and

mucosa. The colon does not have villi, but due to presence of plicae semilunares (crescentic folds) the intestinal surface of the colon is increased to approximately 1300 cm². CDDS is primarily dependent on the following physiological factors; they are the pH level, the transit time and the microbial environment in the colon, which are governing the release rate of drug from different designs of CDDS (Vyas and Roop, 2006, Vincent et al.2002). Different properties of GIT were given in (Table 1) and different enzymes present in colon, which are responsible for microbial degradation, were reported by Vincent et al (2002).

Table 1: Properties of Gastro Intestinal Tract

Region of GIT	Property	Measured value
Total GIT	Surface area	2-10 ⁶ cm ²
Small intestine	Length	20-30 cm
-Duodenum		150-250 cm
-Jejunum		200-350 cm
-Ileum		
Large intestine	Length	6-7 cm
-Cecum		20 cm
-Ascending colon		45 cm
-Descending colon		30 cm
-Transverse colon		40 cm
-Sigmoid colon		12 cm
-Rectum		3 cm
-Anal canal		
Small intestine	Internal diameter	3-4 cm
Large intestine		6 cm
Stomach	p ^H	1-3.5
Duodenum		5-7
Jejunum		6-7
Ileum		7
Colon		5.5-7
Rectum		7
Colon	Redox potential	- 415
-Right		- 400
-Mid		- 380
-Left		

COLONIC ABSORPTION OF DRUGS

The surface area of the colon is much less compared to small intestine and is compensated by absence of endogenous digestive enzymes and long residence time of colon (10-24 hours). Different factors affecting colonic absorption were reported by Vincent et al (2002).

- Passes through colonocytes (Trans cellular transport).
- Passes between adjacent colonocytes (Para cellular transport).

Transcellular absorption involves the passage of drugs through cells and thus the route for most lipophilic drugs takes, where as paracellular absorption involves the transport of drug through the tight junctions between the cells and is the route of most hydrophilic drugs (Vyas and Roop, 2006). Drugs shown to be well absorbed include glibenclamide, diclofenac, theophylline, ibuprofen, metoprolol and oxyprenolol. Drugs shown to be less absorbed include furosemide, pyretanide, buflomedil, atenolol, cimetidine, hydrochlorothiazide, lithium and ciprofloxacin (Sarasija et al. 2000). Different types of absorption enhancers used in CDDS reported by Vincent et al (2002).

DRUGS SUITABLE FOR CDDS

Based on literature review, the following different categories of drugs are suitable for colon drug delivery.

- Drugs used to treat irritable bowel disease (IBD) require local delivery at drug to colon e.g. sulfasalazine, olsalazine, mesalazine, steroids like fludrocortisone, budesonide, prednisolone and dexamethasone.
- Drugs to treat colonic cancer require local delivery e.g. 5-fluorouracil, doxorubicin, and methotrexate.
- Protein and peptide drugs - eliminating drug degradation e.g. growth hormones, calcitonin, insulin, interleukin, interferon and erythropoietin.

- To treat infectious diseases (amoebiasis & helminthiasis) - requires site specific delivery e.g. metronidazole, mebendazole and albendazole,
- To treat rheumatoid arthritis (NSAIDS), nocturnal asthma, angina require delay in absorption due to circadian rhythms
- Drugs showing more selective absorption in colon than small intestine due to small extent of paracellular transport e.g. glibenclamide, diclofenac, theophylline, ibuprofen, metoprolol, and oxyprenolol.

DIFFERENT APPROACHES

Prodrug Approach

A prodrug is pharmacologically inactive derivative of a parent drug molecule that requires spontaneous enzymatic transformation in vivo to release the active drug (Sinha and Rachana, 2001a). In this method the prodrugs (Table 2) are designed to undergo minimum absorption and hydrolysis in the upper GIT and undergo enzymatic hydrolysis in the colon, there by releasing the active drug moiety from the carrier.

Different types of conjugates were used to prepare 5-ASA prodrugs, which are succeed in releasing the 5-ASA in colonic region. They are biodegradable poly (ether-ester) azo polymers (Samyn et al.1995), azo-linked polymeric prodrugs (Etienne et al.1996), acrylic type polymeric prodrugs (Soodabeh et al.1997) and cyclodextrin prodrugs (Kaneto et al.1997). Glucuronide prodrugs were developed for corticosteriod to deliver the drug to the large intestine of colitic rats (Harold et al.1997). Azo-containing urethane analogues synthesized for colon drug delivery. A urethane-based analogue containing an azo aromatic linkage in the backbone was synthesized by reacting touline-2, 6-diisocyanate with a mixture of an aromatic azodiol (Chavan et al. 2001).

Cyclodextrin prodrugs were prepared by conjugating 5-ASA on to the hydroxyl groups of α -, β -, γ -cyclodextrins through an ester linkage and investigated the release in cecum and colon. After oral administration in rats the conjugate passed through stomach and small intestine without degradation or absorption and in the cecum and/or colon site-specific degradation of conjugate released 5-ASA (Mei et al. 2005). An azo prodrug of 5-ASA with histidine was synthesized for targeted drug delivery to the inflamed gut tissue in inflammatory bowel disease. The synthesized prodrug was found to be equally effective in mitigating the colitis in rats, as that of sulfasalazine without the ulcerogenicity of 5-ASA and adverse effects of sulfasalazine (Nagpal et al. 2006).

In a recent study by Yunjin et al. (2006), explained the potential of 5- amino salicyltaurine as a colon specific prodrug of 5ASA by in vivo evaluation to treat experimental colitis. The prodrug was prepared by conjugating 5ASA with taurine and tested in 2,4,6, trinitrobenzene sulfonic acid (TNBS) induced colitis rats. Taurine conjugation of 5-ASA greatly reduced absorption of 5-ASA from the intestine. Oral administration of the conjugate not only increased the colonic delivery efficiency of 5-ASA but also decreased the systemic absorption of free 5-ASA as compared to other conjugates prepared with glycine and aspartic acid. Taurine conjugate of 5-ASA is slightly more effective than sulfasalazine in alleviating the colonic inflammation induced by TNBS. N-Nicotinoylglycyl-2-(5-fluorouracil-1-yl)-D, L-glycine was synthesized as a prodrug of 5-fluorouracil colon specific drug delivery (Lee et al. 2007).

P^H-Dependent System

The basic principle in this method is the coating of the tablets/pellets etc with various pH sensitive polymers (given in Table 2), which will produce delayed release and also give protection from gastric fluids. Selection of polymers is an important thing. The selected polymers for colon targeting should be able to withstand the pH of the stomach and small intestine. Methacrylic acid esters most

commonly used polymers for colon targeting because they are soluble at above pH 6. The ideal polymer should be able to withstand the lower pH of the stomach and of the proximal part of the small intestine but able to disintegrate at neutral or shortly alkaline pH of the terminal ileum and preferably at ileocecal junction. Eudragit L and Eudragit S are widely used in the colon targeting because Eudragit L is soluble at pH 6 or above and Eudragit S is soluble at pH 7 or above and the combination of these polymers give the desirable release rates.

A novel colon-specific drug delivery system was developed with methacrylate derivatives of 5-ASA using pH sensitive swelling and drug release properties (Davaran et al. 2001). Composite film coated tablets of 5-ASA were prepared for colon specific delivery. In this method 5-ASA core tablets were prepared and coated with dispersion contained Eudragit RS and dessterrified pectin, polygalacturonic acid, or its potassium and sodium salts. Negligible drug release occurred during first five hours where the coated tablets were in the stomach and small intestine. After that the release of 5-ASA from coated tablets occurred linearly as a function of time due to the action of pectinolytic enzymes (Sriamornsak et al. 2003).

A comparison study of the usual enteric-coated polymers viz. Eudragit, Cellulose acetate phthalate with Shellac and Ethyl cellulose as carriers for colon specific drug delivery was conducted to select a suitable carrier. In this study lactose based indomethacin tablets were prepared and coated with one of the above coating polymers to a varying coating thickness. From the dissolution data at a coat concentration of 3% shellac provided the most appropriate polymer coat for colon-specific drug delivery. Variation in the shellac coat thickness can facilitate drug delivery to terminal ileum, distal or proximal colon (Sinha et al. 2003).

EUDRACOLTM is a novel pH and time controlled multiple unit colon drug delivery systems in which the pellets coated with Eudragit RL /RS and Eudragit FS 30D. Caffeine is used as marker drug

for pharmacokinetic studies using the multi particle principle and delayed release in the colon; reduction of dosing frequency may be achieved. Due to its specific coating structure, the Eudracol system offers a new dimension for colon drug targeting via the oral route (Brigitte et al 2003). 5-ASA pellets were coated with the enteric coating solution containing different ratios at Eudragit L-100 and Eudragit S-100 for colon drug delivery. The release of 5-ASA is depending on the thickness of the layer and the ratio of Eudragit copolymers (Gang et al. 2004). P^H-sensitive hydrogels were prepared for colonic delivery of therapeutic peptides, proteins. New pH-sensitive glycopolymers were developed by free radical polymerization of methacrylic acid and 6-hexandiol diacrylate and 6-hexandiol propoxylate diacrylate (Mahkam M, 2007).

Time-Dependent System

The basic principle involved in the system is the release of drug from dosage form should be after a predetermined lag time to deliver the drug at the right site of action at right time and in the right amount (Shweta, et al., 2006). Colon targeting could be achieved by incorporating a lag time into formulation equivalent to the mouth to colon transit time. A nominal lag time of five hours is usually considered sufficient to achieve colon targeting. In this method the solid dosage form coated with different sets of polymers (listed in Table 2) and the thickness of the outer layer determines the time required disperse in aqueous environment.

Colon drug delivery system of diclofenac sodium (DS) was developed using time dependent approach. In this, diclofenac sodium tablets were coated with ethylcellulose in ethanol solution cooling diethyl phthalate as a plasticizer and PEG 400 as channeling agent. The lag time of DS release was primarily controlled by thickness of ethylcellulose coating layer. By increasing the thickness of the coating layer, longer the lag time of DS release (Gang et al. 2004).

Formulation of fast release enteric coated tablets for colon drug delivery using two different approaches. The first one is using super disintegrate and the second one is based on osmogen. In the first approach core tablets (celecoxib as a model drug) were prepared using different concentrations of super disintegrates like cross-linked PVP. In second approach concentrations tablets were prepared using potassium chloride, sodium chloride as osmogen. Then they are coated with Eudragit L-100: Eudragit S-100 in the ratio of 1:5 to achieve a desired thickness. The tablets with super disintegrates are fast released where the tablets with osmogen are sustain released. The coat weight determines the lag phase that required eliminating the release in stomach and small intestine (Sinha et al. 2006).

Hydroxy Propyl Methyl Cellulose (HPMC) compression coated tablets of 5-fluorouracil were studied for colon drug delivery that based on time-dependent approach. In this, the core tablet was prepared by wet granulation method and then coated with 50% of HPMC/lactose coat powder by compression-coating method. Drug release characteristics were evaluated in distilled water by using a Chinese pharmacopoeia rotatable basket method (Wu B et al. 2007).

Micro flora Activated System

The basic principle involved in this method is degradation of polymers coated on the drug delivery system by microflora present in colon and there by release of drug load in colonic region because the bioenvironment inside the human GIT is characterized by presence of complex microflora, especially the colon is rich in microorganisms (Sinha, Rachana, 2003). In this method drugs and/or dosage forms are coated with the biodegradable polymers (Table 2) i.e., the polymers degrade due to influence of colonic microorganisms. When the dosage form passes through the GIT, it remain intact in the stomach and small intestine where very little microbial degradable activity is present which is insufficient for cleavage of the polymer coating.

Table-2: Materials used in Formulation of CDDS

Prodrug conjugates	P^H-Sensitive Polymers	Materials used In Time-Dependent System	Microbial degradable polymers
Azo bond conjugates	Eudragit L-100	Hydroxy Propyl Methyl Cellulose	Chitosan
Amino acid (Polypeptide) conjugates	Eudragit S-100	Hydroxy Ethyl Cellulose	Pectins
	Eudragit L-30 D		Guar gum
Glycoside conjugates	Eudragit L-100-55	Ethyl Cellulose	Dextrans
Glucuronide conjugates and Sulphate conjugates	Eudragit F S 30 D	Microcrystalline Cellulose	Inulin
Polymeric conjugates	Poly Vinyl Acetate Phthalate	Hydroxy Propyl Methyl Cellulose Acetate Succinate	Lactulose
	Hydroxy Propyl Methyl Cellulose Phthalate 50		Amylose
Cyclodextrin conjugates	Hydroxy Propyl Methyl Cellulose Phthalate 50	Lactose/Behinic acid	Cyclodextrins
Dextran conjugates	Hydroxy Propyl Methyl Cellulose Phthalate 55		Alginate
	Hydroxy Propyl Ethyl Cellulose Phthalate	Locust bean gum	
	Cellulose Acetate Phthalate	Chondroitin sulphate	
	Cellulose Acetate Trimellate	Boswellia gum	

5-ASA pellets were coated with amylose for colon drug delivery, in which amylose coating solution was prepared along with Ethocel, Eudragit RS/RL 30D and Aquacoat ECD 30 (Snezana et al. 1996). Chitosan capsules were developed for colon specific delivery of insulin and its absorption was improved by addition of absorption enhancers (sodium glycocholate, sodium oleate) and protease

inhibitors like bacitracin, aprotinin (Hideyuki et al. 1997). Low swelling guar gum prepared by cross-linking with glutaraldehyde that is used as a colon-specific drug carrier (Irit et al. 1998). Chitosan succinate and chitosan phthalate were synthesized by reacting the chitosan separately with succinic anhydride and phthalic anhydride. These semisynthetic polymers produced stable matrices of diclofenac sodium for colon specific delivery that had more resistance to acidic condition and improved drug release profile under basic conditions (Khaled et al. 1999).

Organic acids like succinic acid, tartaric acid and citric acid were used as excipients in matrix granules to modify the drug release for colon-specific drug delivery (Nykanen et al. 1999). Amylose-Ethylcellulose film coatings obtained from organic-based solvents were investigated as potential vehicles for colon drug delivery. In this method amylose-butanol dispersion and ethylcellulose in ethyl lactate/ethanol/propanol with dibutyl sebacate as plasticizer were mixed in various proportions and coated on 5-ASA pellets to achieve desired thickness. The drug release regulating parameters are thickness of coating and ratio of amylose to ethylcellulose. The release of drug is irrespective of the solvent used for coating. Formulation containing 1 part amylose and 1 part ethylcellulose of coating thickness, 15% TWG, gives desired release profiles of 5-ASA for colon targeting (Lee et al. 2000).

Phosphated cross-linked guar gum was prepared for colon-specific drug delivery. Guar gum cross-linked with increasing amounts of trisodium trimetaphosphate to reduce its swelling properties for use as a vehicle in oral delivery formulations, especially drugs aimed at localizing in the distal portions of the small bowel. Swelling of guar gum in artificial GI fluids was reduced from 100-120-fold to 10-35-fold depending on the amount of cross linker used (Irit et al. 2000).

Colon target drug delivery system for mebendazole was developed using guar gum as a carrier. In this method mebendazole matrix tablets containing various proportions of guar gum were prepared by wet granulation technique using starch paste as a binder. From the results 20% and 30% guar gum

tablets were provided targeting of mebendazole for local action in the colon (Krishnaiah et al. 2001). The α -cyclodextrin derivate of prednisolone-21-succinate showed anti-inflammatory activity with low adverse effects when compared to prednisolone alone by intra colonical administration to rats with 2,4,6, trinitrobenzene sulfonicacid-induced colitis. The conjugate can alleviate the systemic adverse effect of prednisolone while maintaining the therapeutic activity of prednisolone (Hideki et al. 2001).

A chitosan-dispersed system (CDS) was developed for colon- specific drug delivery, in which the capsule containing acetaminophen was coated with the suspension containing chitosan powder and Eudragit RS, formed a drug release-regulating layer around the capsule. Outer enteric coating layer prevent the dissolving of chitosan under acidic pH. The resultant enteric-coated CDS capsules reached the large intestine with in one to three hours after oral administration and they were degraded at the colon in beagle dogs (Norihito et al. 2002). Masataka et al. (2002), Libo et al. (2003) were studied about the lactulose as a carrier for colon-specific drug delivery by microbial degradation in colon.

Enteric-coated pectin based matrix tablets were prepared for colonic delivery of theophylline. This approach takes advantage of the combination of pH-sensitive method and microbial-triggered system. In this method theophylline-colon biodegradable pectin matrix tablets were prepared and coated with enteric coating solution (Eudragit S100 in acetone) to overcome the poor compactability of pectin. Emdex, a hydrophilic directly compressible material was used to prepare tablets by direct compression (Paola et al. 2003). The new quaternized chitosan i.e. triethyl chitosan (TEC) is evaluated in pharmaceutical approaches and proved that there is a significant increase in absorption of poorly absorbed compounds in colon specific drug delivery system (Parisa et al. 2004).

Calcium pectinate beads were prepared for colon specific delivery of therapeutic peptides like bovine serum albumin (BSA) by extruding BSA-loaded pectin solution to an agitating calcium chloride solution and gelled spheres were formed instantaneously by an ionotropic gelation reaction.

The drug release was regulated by concentration of pectin, concentration of calcium chloride and total drug loading (Atyabi et al. 2005). The HPMA Copolymer (N-(2-hydroxy propyl) methacrylamide)-9 amino camptothecin conjugate containing a spacer was synthesized and characterized for oral colon specific drug delivery. The drug delivery system has potential in the treatment of colon cancer (Song-Qi et al. 2006 and Shinji et al. 2001). Zinc pectinate beads formed the strongest network matrix in comparison with calcium pectinate and suggested the zinc pectinate beads as efficient carriers for specific drug delivery to colon (Chambin et al. 2006).

Metronidazole tablets were prepared using various polysaccharides like guar gum, xanthan gum, pectin, carrageenan, β -cyclodextrin for colon specific drug delivery to treat amebiasis (Mundargi et al. 2007). 5-Fluorouracil compression coated tablets were prepared for colonic release of drug using xanthan gum, boswellia gum and HPMC as the coating materials (Sinha et al. 2007).

CDDS of 5-fluorouracil was developed using pectin-ethyl cellulose as a film coat with Fluidized bed coater (Wei et al. 2007).

Combination of Different Approaches of CDDS

An oral colonic drug delivery system of 5-ASA was developed using combination of pH-dependent, time-based and enzyme degradable approaches. The pellets were coated with three functional layers i.e. the outer EudragitL30D-55 layer for protection against GI fluids, the intermediate layer of ethyl cellulose to inhibit the drug release during passage through the small intestine and the inner layer of pectin for swelling and enzyme-degradation. In vitro release studies indicated that the coated pellets completely protected the drug release in 0.1M HCl while the drug release was delayed for three to four hours in pH 6.8 phosphate buffer (Fude et al. 2007).

Pulsatile device was formulated to achieve time- or site-specific release of theophylline based on chronopharmaceutical consideration. The basic design consists of an insoluble hard gelation capsule body filled with Eudragit microcapsules of theophylline and sealed with a hydrogel plug and finally the enteric device was enteric coated. In this approach, pH sensitive and time dependent delivery systems were combined. In this the thickness of enteric coat is a measure of protection from stomach and intestine pH. Different hydrogel polymers were used as plugs to maintain a suitable lag period. The hydrophilic polymer content is a measure of delayed release of theophylline from microcapsules (Mastrholimath et al. 2007).

Pectin based CDDS of 5-fluorouracil was developed using calcium pectinate gel. Calcium pectinate gel beads were prepared by ionotropic gelation method followed by enteric coating with Eudragit S-100 and evaluated using USP paddle type dissolution apparatus in different simulated mediums (Jain et al. 2007).

A new microbial-triggered colon targeted osmotic pump (MTCT-OP) was developed for CDDS based on chitosan for a model drug, budesonide. The combination of osmotic technology and microbial-triggered mechanism had a high potential to deliver to drug load in colonic region. In this method the core tablet of budesonide was prepared with chitosan, which is used to produce osmotic pressure, and to form the insitu delivery pores for colon-specific drug release. Cellulose acetate in acetone along with chitosan (as pore forming agent) was coated on tablet as a semipermeable membrane and finally coated with Eudragit L-100-55 in ethanol as an enteric coating layer that could prevent cellulose acetate membrane from forming pore or rupture before reaching colon region. Budesonide release from developed system was inversely proportional to the osmotic pressure to the release medium (Liu et al 2007).

Hydrogel based CDDS

Amydated pectin hydrogel beads prepared for colon specific delivery of indomethacin and sulfamethoxazole (Munjere et al 1997). Glutaraldehyde cross-linked dextran capsules were prepared for colon targeting. Along with magnesium chloride and PEG 400 in water the capsule caps and bodies were prepared on nylon molding pins. Then the dextran capsules were filled with model drug (Hydrocortisone) and drug release was studied. The drug release pattern was suitable for colon specific delivery (Bronsted et al. 1998). The hydrogels formed by cross-linked polyvinyl alcohol were suitable for colon specific drug delivery systems. In this method polyvinyl alcohol of different molecular weights was corss-linked with succinyl, adipoyl, or sebacoyl chloride to obtain hydrogel-forming polymers. The hydrophilic drugs like diclofenac sodium, propranolol hydrochloride and vitamin B6 hydrochloride were used as model drugs (Orient et al. 2001). Methacrylated inulin hydrogels designed for colon targeting the proteins like Bovine serum albumin or Lysozyme (Vanden et al. 2003). Organic redox-initiated polymerization technique was used to fabricate pH responsive hydrogels for colon specific delivery (Emmanuel et al. 2003).

Glutaraldehyde corss-linked guar gum hydrogel discs were prepared as vehicles for colon specific drug delivery of ibuprofen. Percent drug release increased with glutaraldehyde concentration. Cross-linking decreased the swelling of guar gum. The fabricated hydrogels discs may prove to be beneficial as colon-specific drug delivery vehicles for poorly water-soluble drugs like ibuprofen (Adit et al. 2006).

Novel complex hydrogel beads were prepared using pectin and zein for colon-specific drug delivery. Pectin/Zein complex hydrogel beads showed the capability to protect incorporated drugs from premature release into stomach and small intestine. The inclusion of a small portion of zein (a protein from corn) in to the pectin efficiently suppressed the swelling behavior of pectin, thus

stabilizing the structural property of the pectin networks. Like wise the pectin networks protected the bound zein from protease digestion. These properties made pectin/zein complex beads a promising system for colon specific drug delivery (Linshu et al. 2006). Cross-linked HPMC hydrogels were synthesized and used to develop 5-ASA colon drug delivery system (Davaran et al. 2007).

NOVEL DRUG DELIVERY SYSTEMS FOR CDDS

Now a days the basic CDDS approaches are applied to formulate novel drug delivery systems like Multiparticulate systems, Microspheres, Liposomes, Microencapsulated particles etc.

Multiparticulate systems

Multiparticulates (pellets, non-peariles etc.) are used as drug carriers in pH-sensitive, time-dependent and microbially control systems for colon targeting. Multiparticulate systems have several advantages in comparison to the conventional single unit for controlled release technology, such as more predictable gastric emptying and fewer localized adverse effect than those of single unit tablets or capsules (Laila and Sanjeev, 2006).

A multiparticulate dosage form was prepared to deliver active molecules to colonic region, which combines pH dependent and controlled drug release properties. This system was constituted by drug loaded cellulose acetate butyrate (CAB). Microspheres loaded by an enteric polymer (Eudragit S). Here the enteric coating layer prevents the drug release below pH 7. After that CAB microspheres efficiently controlled the release of budesonide, which is depended on the polymer concentration in the preparation (Marta, Jose et al. 1998). Azo polymer coated pellets were used for colon-specific drug delivery to enhance the absorption of insulin and (Asu^{1,7}) Eel calcitonin (Hideyuki et al. 2001). A multiparticulate chitosan dispersed system (CDS) was prepared for colon drug delivery and it was composed of the drug reservoir and the drug release-regulating layer, which was composed of water insoluble polymer and chitosan powder. The drug reservoir was prepared by drug containing

multiparticulates like Non peariles in the study. In this study the multiparticulate CDS was adopted not only for colon specific drug delivery but also for sustained drug delivery (Norihito et al. 2003).

A multiparticulate system combining pH sensitive property and specific biodegradability was prepared for colon targated delivery of metronidazole. The multiparticulate system was prepared by coating cross-linked chitosan microspheres exploring Eudragit L-100 and S-100 as pH sensitive polymers. The in-vitro drug release studies shows that no release of drug at acidic pH and higher drug release was found in presence of rat caecal contents indicating susceptibility of chitosan matrix to colonic enzymes released from rat caecal contents (Chourasia and Jain 2004). High-Amylose cornstarch and Pectin blend microparticles of diclofenac sodium for colon-targeted delivery were prepared by spray drying technique. The blending of high-amylose cornstarch with pectin improved the encapsulation efficiency and decreased the drug dissolution in the gastric condition from pectin-based microparticles. The drug released in colonic region by the action of pectinase from microparticles (Kashappa, 2005).

Masataka et al. (2006) investigated the effect of sodium glycocholate as an absorption promoter on orally administrated insulin absorption utilizing a colon-targeted delivery system. A novel insulin colon-targeted delivery system (Insulin- CODES) contains insulin, lactulose as a trigger for colon-specific release, citricacid as a solubilizer of insulin, meglumine as a pH adjusting agent and sodium glycocholate as an absorption promoter.

Microspheres of anti-cancer drugs

Cross-linked guar gum microspheres containing methotrexate were prepared and characterized for local release of drug in the colon for efficient treatment of colorectal cancer. In this method glutaraldehyde was used as a cross-linking agent and guar gum microspheres were prepared by emulsification method. From the results of in vitro and in vivo studies the methotrexate loaded cross-

linked guar gum microspheres delivered most of the drug load (79%) to the colon, where as plain drug suspensions could deliver only 23% of there total dose to the target tissue (Mohini et al. 2006).

Colon specific microspheres of 5-fluorouracil were prepared and evaluated for the treatment of colon cancer. In this method core microspheres of alginate were prepared by modified emulsification method in liquid paraffin and by cross-linking with calcium chloride. The core microspheres were coated with Eudragit S-100 by the solvent evaporation technique to prevent drug release in the stomach and small intestine. The results showed that this method had great potential in delivery of 5-fluorouracil to the colon region (Ziyaus et al. 2006).

Other novel drug delivery systems

A new microparticulate system containing budesonide was prepared by microencapsulation for colon specific delivery (Marta et al 2001).

In the study by Liu et al. (2003) a novel formulation for bee venom peptide was developed using coated calcium alginate gel beads-entrapped liposome and investigated for colon specific drug delivery in vitro. The release rate of bee venom from formulation was dependent on the concentration of calcium and sodium alginates and the amount of bee venom in the liposome, as well as coating. A human γ -scintigraphy technique was used for in vivo studies and the results showed that this formulation had great potential for colon-specific drug delivery. A novel colon specific drug delivery system containing flubiprofen microsponges was designed. Microsponges containing flubiprofen and Eudragit RS100 were prepared by quasi-emulsion solvent diffusion method and/or flubiprofen was entrapped in to a commercial microspunge-5640 system using entrapment method. Using these flubiprofen microsponges the colon specific tablets were prepared using triggering mechanism. The particulate form (microsponges) has been used to provide more uniform distribution

of the drug in the colon and help the drug to spread on the colon surface in an appropriate way (Mine et al. 2006).

EVALUATION OF CDDS

The drug release in the colonic region from different CDDS is evaluated by different methods of in vitro and in vivo release studies, which show the success rate of different designs of colon drug delivery systems. Depending upon the method of preparation different evaluation methods are proposed. A successful colon specific drug delivery system is one of that remains intact in the physiological environment of stomach and small intestine, but releases the drug in the colon.

In-vitro Evaluation

Different in vitro methods are used to evaluate the colonic drug delivery systems. In in-vitro studies the ability of the coats/carriers to remain intact in the physiological environment of the stomach & small intestine is assessed by drug release studies in 0.1N HCl for two hours (mean gastric emptying time) and in pH 7.4 phosphate buffer for three hours (mean small intestine transit time) using USP dissolution apparatus. In case of micro flora activated system dosage form, the release rate of drug is tested in vitro by incubating in a buffer medium in the presence of either enzymes (e.g., pectinase, dextranase) or rat/guinea pig / rabbit caecal contents. The amount of drug released at different time intervals during the incubation is estimated to find out the degradation of the carrier under study (Libio et al, 2002).

In-vivo Evaluation

Like other controlled release delivery systems, the successful development of the CDDS is ultimately determined by its ability to achieve release in colonic region thus exerts the intended therapeutic effect. When the system design is concerned & prototype formulation with acceptable in vitro characteristics is obtained, in vivo studies are usually conducted to evaluate the site specificity of

drug release and to obtain relevant pharmacokinetic information of the delivery system. Although animal models have obvious advantages in assessing colon specific drug delivery systems, human subjects are increasingly utilized for evaluation of this type of delivery systems. The preferable animals to evaluate CDDS are rats, guinea pigs and dogs (Libio et al, 2002).

γ -scintigraphic studies were conducted in human volunteers with technetium-99m-DTPA as tracers in sodium chloride core tablets compression coated with guar gum showed that the gum coat protect the drug (tracer) from being released in the stomach and small intestine. On entering the ascending colon, the tablets commenced to release the tracer indicating the breakdown of gum coat by the enzymatic action of colonic bacteria (Krishnaiah et al. 1998a). Technetium-99m-DTPA was used as a tracer for γ - scintigraphy evaluation of colon specific guar gum directly compressed matrix tablets in human volunteers (Krishnaiah et al. 1998b). The scintigraphic evaluation conducted for capsule type colon specific drug delivery system in human healthy volunteers (Ishibashi et al. 1998). In a study by Krishnaiah et al. (2001), showed the effect of metronidazole and tinidazole (antimicrobial agents) on the release of albendazole from guar gum based colon specific matrix tablets. The active antimicrobial agents (7 days) treatment of rat caecal content decreased the release of albendazole due to decreased levels of anaerobic bacteria present in rat. Sangalli et al. (2001) studied the evaluation of chronotropicTM oral system to achieve time and/or site-specific release. In this study in vitro drug release studies were carried out in a USP 24 paddle apparatus. The in vivo testing, performed on healthy volunteers, envisaged the HPLC determination of antipyrine salivary concentration and a γ -scintigraphic investigation to point out the break-up of the units occurred in the colon.

The suitability of different tracers like Tc-DTPA (technisium-99m-diethylene triamine penta-aceticacid) and Tc-sulphur colloid studied for γ - scintigraphy evaluation of CDDS in healthy human volunteers and concluded that DTPA is a suitable targeting for 99m-Tc for evaluation of CDDS

containing water soluble drugs by γ - scintigraphy (Krishnaiah et al. 2002). The suitability of locust bean gum and chitosan for bacterially triggered colon specific drug delivery system was studied by in vitro and in vivo drug release studies (Chellan et al. 2002). In vitro evaluation studies were carried out for colon specific tablets containing different binders like xanthan gum, guar gum, chitosan and Eudragit E. From the results formulation with chitosan and Eudragit E would be highly site specific (Sinha et al. 2002). In a study by Jinhe et al. (2002) proved that apparatus III (reciprocating cylinder method) was more convenient and efficient than apparatus-II (paddle type) by producing various programmable options in sampling times, agitation rates and medium changes and suggested that apparatus-III approach has better potential for in vitro evaluation of CDDS. Summary of general dissolution on conditions for paddle (USP APP-II) and reciprocating cylinder methods (USP APP-III) was reported by Jinhe et al. (2002).

In vitro evaluation studies were conducted for chitosan-containing microparticulate system for colon drug delivery. In this study fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) was used as a model drug. The chitosan hydrogel beads which containing triphosphate as counter ion. The protein release experiments were carried out in vitro under different conditions to simulate the pH and times likely to be encountered drug intestinal transit to the colon. Release of FITC-BSA from the chitosan beads was studied in sealed 25ml conical flasks in a Magniwhirl* constant temperature shaker bath at 37°C and 60 SPM. Enzymatic degradations of chitosan by pancreatin and by porcine pancreatic lipase present in simulated intestinal fluid were studied using a viscometric procedure (Hua et al. 2002). The pharmacokinetic evaluation of guar gum based colon-targeted tablets of mebendazole against an immediate release tablet was carried out in human volunteers. Six healthy volunteers participated in the study and a crossover design was followed. In this study, on oral administration of colon-targeted tablets mebendazole started appearance in the

plasma at five hours and reached the peak plasma concentration at 9.4 ± 1.7 hrs (T_{max}) where as the immediate release tablets produced at 3.4 ± 0.9 hrs (T_{max}) the results of the study indicated that the guar gum based colon targeted tablets of mebendazole did not release the drug in stomach and small intestine, but delivered the drug to the colon resulting in a slow absorption of the drug and making the drug available for local action in colon (Krishnaiah et al. 2003).

The colon-specific matrix tablets of mesalazine with guar gum were evaluated *invitro* and *in vivo* studies. *In vitro* dissolution studies using a flow-through cell apparatus with and without galactomannase enzyme. *In-vivo* studies conducted in healthy humans using X-ray imaging technique to monitor the tablets throughout the GI system in which barium sulphate as a marker (Fatmanual et al. 2004). Tablets consisting of flubiprofen microsponges were developed for colon specific delivery and dissolution test was conducted in USP rotating paddle apparatus at $37 \pm 0.5^{\circ}\text{C}$ and 50 RPM. Initial drug release studies were done in 750 ml of 0.1 N HCl for two hours. Then 250 ml of 0.2 M trisodium phosphate solution was added to the dissolution media and the pH was adjusted to 6.8 with 2N HCl for eight hours. Samples were withdrawn after regulated time intervals and analyzed spectrophotometrically at 248 nm. For the study of enzymatic degradation same method was used, but at eighth hour pectinexultra SP-L was added to the dissolution media to simulate the enzymatic action to the colonic bacteria (Mine et al. 2006).

CONCLUSION

From past two decades, considerable amount of research work has been carried out in the area of colon targeting. By considering the advantages of CDDS like providing friendlier environment for protein and peptide drugs that reducing the adverse effects in the treatment of colonic diseases, site-specific release to treat colonic cancer, amoebiasis, and helminthiasis etc, minimizing the extensive first pass metabolism of steroids and produces delay in absorption of drugs to treat rheumatoid

arthritis, angina and nocturnal asthma etc., different approaches are designed to develop colonic drug delivery system. The release of drug load in colon region is depended on pH of GIT, gastro intestinal transit time and microbial flora and their enzymes to degrade coated polymers and breaking bonds between carrier molecule and drug molecule. The preferred CDDS is that should release maximum drug load in colon region. Among different approaches the pH dependent system is less suitable than others due to the large inter and intra subject variation in the gastro intestinal pH, but gives better results with combination of time-dependent system, microbially activated system and others. Different polymers are used to prepare CDDS by various approaches and are evaluated for their efficiency and safety.

REFERENCES

1. Aditi Das, Saurabh Wadhwa and Srivastava AK, Cross-linked guar gum hydrogel discs for colon specific delivery of Ibuprofen. Formulation and Invitro evaluation. *Drug Delivery*, (2006). 13:139-142.
2. Atyabi F, Inanloo K and Dinarvanal R, Bovine serum albumin-loaded pectinate beads as colonic peptide delivery system: preparation and in vitro characterization. *Drug Delivery*, (2005) 12: 367-375.
3. Brigitte Skalsky, Markus Rudolph, Gerhard Renner et al. (2003) In-vivo evaluation of EUDRACOL™, A novel pH and time controlled multiple unit colonic drug delivery systems. Eudracol Abstract Final doc: CS-1.
4. Brondsted H, Andersen C and Hovgaard L, Cross-linked dextran-a new capsule material for colon targeting drugs. *Journal of controlled Release*, (1998) 53: 7-13.

5. Chambin O, Dupuls G, Champion D, colon-specific Drug delivery: Influence of solution reticulation properties upon pectin beads performance. *International Journal of Pharmaceutics*. (2006) 321: 86-93.
6. Chavan MS, Sant VP and Nagarsenker MS, Azo-containing urethane analogues for colonic drug delivery: synthesis, characterization and in vitro evaluation. *Journal of Pharmacy and Pharmacology*, (2001) 53: 895-900.
7. Chellan Vijaya Raghavan, Chithambaram Muthulingam, Joseph Amaladoss Josephine Leno Jenita, An in vitro and in vivo investigation in to the suitability of bacterially triggered delivery system for colon targeting. *Chem.Pharm.Bull*, (2002)50(7): 892-895.
8. Chourasia MK and Jain SK, Pharmaceutical approaches to colon targeted drug delivery systems. *J Pharm Pharmaceut Sci*, (2003) 6(1): 33-66.
9. Chourasia MK and Jain SK, Designed and development of multiparticulate system for target drug delivery to colon. *Drug Delivery*, (2004)11: 201-207.
10. Davaran S, Rashidi M R and Hashemi M, Synthesis and characterization of methacrylic derivatives of 5-amino salicylic acid with pH-sensitive swelling properties. *AAPS Pharm Sci tech*, (2001)2(4): 1-6.
11. Davaran S, Rashidi MR, Khani A, Synthesis of chemically cross-linked hydroxy propyl methyl cellulose hydrogels and their application in controlled release of 5-amino salicylic acid. *Drug Dev Ind Pharm*, (2007) 33(8): 881-887.
12. Emmanuel O, Akala, Oluchi Elekwachi, Vantoria Chase, Organic Redox- initiated polymerization process for the fabrication of hydrogels for colon-specific drug delivery. *Drug Development and Industrial Pharmacy*, (2003)29(4): 375-386.

13. Etienne Schacht, An Gevaert, El Refaie Kenawy, Polymers for colon-specific drug delivery. *Journal of Controlled Release*, (1996) 39: 327-338.
14. Fatmanur Tagcu-pemiroz, Fusin Acarturk, Sevgi Jakka, In-vitro and In-vivo evaluation of mesalazine-guar gum matrix tablets for colonic drug delivery. *Journal of Drug Targeting*, (2004) 12(2): 105-112.
15. Fude C, Lei Y, Jie J, Preparation and in vitro evaluation of pH, time-based and enzyme-degradable pellets for colonic delivery. *Drug Dev Ind Pharm*, (2007)33(9): 999-1007.
16. Gang Cheng, Feng An, Mei-Juan Zou, Time and pH dependent colon specific drug delivery for orally administered diclofenac sodium and 5-amino salicylic acid. *World J Gastroenterol*, (2004) 10(12): 1769-1774.
17. Girish N. Patel, Gayatri C. Patel, Ritesh B. Patel, oral colon-specific drug delivery: an overview. *Drug Delivery Technology*, (2006)6(7): 62-71.
18. Guy Vanden Mooter, Lies Vervoort and Rennat Kinget (2003) Characterisation of methacrylated Inulin hydrogels designed for colon targeting: Invitro release of BSA. *Pharmaceutical Research* 20(2): 303-307.
19. Harold W. Nolen III, Richard N. Fedorak and David R. Friend (1997) Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rats. *Biopharmaceutics & Drug Disposition* 18(8): 681-695.
20. Hideki Yano, Fumitoshi Hirayama, Hidetoshi Arima et al (2001) Prednisolone-Appended α -Cyclodextrin: Alleviation of systemic adverse effect of Prednisolone after intracolonic administration in 2,4,6-tri-nitro-benzenesulphonicacid-induced colitis rats. *Journal of Pharmaceutical Sciences* 90(12): 2103-2112.

21. Hideyuka Tozaki, Junko Nishioka, Junta Komoike et al. (2001) Enhanced absorption of Insulin and (Asu^{1, 7}) Eel- calcitonin using novel azo polymer-coated pellets for colon-specific drug delivery. *Journal of Pharmaceutical Sciences* 90(1): 89-97.
22. Hideyuki, Junta Komoike, Chika Tada et al (1997) Chitosan capsules for colon-specific drug delivery: Improvement of Insulin absorption from the rat colon. *Journal of Pharmaceutical Sciences* 89(6): 1016-1021.
23. Hua Zhang, Ibrahim.A, Alsarra, Steven H. Naeu (2002). An Invitro evaluation of chitosan-containing multiparticulate system for macromolecule delivery to the colon. *International Journal of Pharmaceutics* 239:197-205.
24. Hyo-Kyung Han, Gordan L. Amidon (2000) Targeted prodrug design to optimize drug delivery. *AAPS Pharm Sci* 2(1): 1-11.
25. Irit Gliko-Kabir, Boris Yagen, Abraham Rubinstein et al. (1998) Low swelling, cross linked Guar and its potential use as colon-specific drug carrier. *Pharmaceutical Research* 15(7): 1019-1025.
26. Irit Gliko-Kabir, Boris Yagen, Abraham Rubinstein et al. (2000) Phosphated cross linked guar for colon-specific drug delivery I. Preparation and physicochemical characterization. *Journal of Controlled Release* 63: 121-127.
27. Ishibashi T, Pitcairn GR, Wilding IR et al (1998) Scintigraphic evaluation of a new capsule – type colon specific drug delivery system in healthy volunteers. *Journal of Pharmaceutical Sciences* 87(5): 531-535.
28. Jack Aurora, Naresh Talwar and Vinayak Pathak (2006) Colonic drug delivery challenges and opportunities – an overview. *European Gastroenterology Review* 2006: 1-6.
29. Jain A, Gupta Y, Jain SK (2007) Potential of calcium pectinate beads for target specific drug release to colon. *J Drug Target* 15(4): 285-294.

30. Jinhe Li, Libo Yung, Sheila M. Ferguson et al. (2002) In-vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES™) in multi-pH media using united states pharmacopoeia apparatus II and III. AAPS PharmSciTech 3(4): 1-9.
31. Kaneto Uekema, Kunihro Minari and Fumitoshi Hirayama (1997) 6^A-O- ((4-biphenyl) acetyl) - α -, - β - and - γ - cyclodextrins and 6^A-O- (((4-biphenyl) acetyl) amino) - α -, - β - and - γ - cyclodextrins: potential prodrugs for colon - specific delivery. J. Med. Chem. 40: 2755-2761.
32. Kashappa Goud H, Desai (2005). Preparation and characteristics of High-Amylose Corn starch/ pectin blend macro particles: A Technical note AAPS Pharm Sci Tech 6(2): E 202-E 208.
33. Khaled Aledeh and Mutasem O. Taha (1999) Synthesis of chitosan succinate and chitosan phthalate and their evaluation as suggested matrices in orally administered, colon-specific drug delivery systems. Arch.Pharm.Pharm.Med.Chem. 332: 103-107.
34. Krishnaiah YSR, Satyanarayana S, Rama Prasad Y.V et al (1998a) Evaluation of guar gum as a compression coat for drug targeting to colon. International Journal of Pharmaceutics. 171: 137-146.
35. Krishnaiah YSR, Satyanarayana S, Rama Prasad Y.V et al. (1998b) Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers. Journal of Controlled Release 55: 245-252.
36. Krishnaiah YSR, Satyanarayana S, Rama Prasad Y.V et al. (2002) In-vivo evaluation of ^{99m}Tc-Sulphur colloid as tracers in colonic drug delivery systems using Gamma scintigraphy in volunteers. J Pharm Pharmaceut Sci 5(1): 24-28.
37. Krishnaiah YSR, Seetha Devi A. Nageshwara Rao L et al. (2001) Guar gum as a carrier for colon specific delivery: Influence of Metronidazole and Tinidazole on in-vitro release of Albendazole from guar gum matrix tablets. J Pharm Pharmaceut Sci 4(3): 235-243.

38. Krishnaiah YSR, Veer Raju P, Dinesh Kumar B et al (2001) Development of colon targeted drug delivery systems for Mebendazole. *Journal of controlled Release* 77: 87- 95.
39. Krishnaiah YSR, Veer Raju P, Dinesh Kumar B et al (2003) Pharmacokinetic evaluation of guar gum-based colon targeted drug delivery systems of Mebendazole in healthy volunteers. *Journal of controlled Release* 88: 95-103.
40. Laila Fatima Ali Asghar and Sanjeev Chandran (2006). Multiparticulate formulation approach to colon-specific drug delivery: Current perspectives *Journal of Pharmaceutical Sciences* 9(3): 327-338.
41. Lee F.Siew, Abdul W.Basit, and Michael Newton J (2000) The potential of organic-based Amylose-Ethyl cellulose film coatings as oral colon-specific drug delivery system. *AAPS PharmSciTech* 1(3): 1515-1521.
42. Lee J, Rho J, Yang Y et al. (2007) Synthesis and in vitro evaluation of N-Nicotinoylglycyl-2-(5-fluorouracil-1-yl)-D, L-glycine as a colon-specific prodrug of 5-fluorouracil. *J Drug Target* 15(3): 199-203.
43. Libio Yang, James S. Chu, Joseph A. Fix (2002) Colon-specific drug delivery: new approaches and in vitro / in vivo evaluation. *International Journal of Pharmaceutics* 235: 1-15.
44. Libo Yang, Shunsunke Watanabe, Jinhe Li et al. (2003) Effect of colonic lactulose availability on the timing of drug release onset in vivo from a unique colon-specific drug delivery system (CODESTM) *Pharmaceutical Research* 20(3): 429-434.
45. Lin Shu Liu, Marshall L. Fishman et al (2006) Pectin/Zein beads for potential colon- specific drug delivery system: synthesis and in vitro evaluation. *Drug Delivery* 13: 417-423.

46. Liu H, Yang XG, Nie SF et al. (2007) Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: screening of formulation variables and in vitro investigation. *International Journal of Pharmaceutics* 332(1-2): 115-124.
47. Liu Xing, Chen Dawei, Xie Liping et al. (2003) Oral colon-specific drug delivery for bee venom peptide: development of a coated calcium alginate gel beads- entrapped liposome. *Journal of Controlled Release* 93: 293 -300.
48. Mahkam M (2007) New pH-sensitive glycopolymers for colon-specific drug delivery. *Drug Deliv* 14(3): 147-153.
49. Marta Rodriguez, Jose Antonio Antunez, Cristina Taboada et al. (2001) Colon-specific delivery of budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats. *Journal of Pharmacy and Pharmacology* 53: 1207-1215.
50. Marta Rodriguez, Jose L, Dolores Torres et al. (1998). Design to a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. *Journal of Controlled Release* 55:67-77.
51. Masataka Katsuma, Shunsuke Watanabe, Hitoshi Kowai et al. (2002) Studies on lactulose formulations for colon-specific drug delivery. *International Journal of Pharmaceutics* 249: 33-43.
52. Masataka Katsuma, Shunsuke Watanbe, Hitoshi Kawai et al. (2006) Effects of absorption promoters on insulin absorption through colon-targeted delivery. *International Journal of Pharmaceutics* 307: 156-162.
53. Mastiholimath VS, Dandagi PM, Samata Jain S et al (2007) Time and pH dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma. *International Journal of Pharmaceutics* 328: 49-56.

54. Mei-Juan Zou, Gang Cheng, Hirokazu Okamoto et al. (2005) Colon-specific drug delivery systems based on cyclodextrin prodrugs: In vivo evaluation of 5-amino salicylic acid from its cyclodextrin conjugates. *World Journal of Gastroenterology* 11(47): 7457- 7460.
55. Mine Orlu, Erdal Cevher, Ahmet Araman (2006) Design and evaluation of colon-specific drug delivery system containing flubiprofen microsponges. *International Journal of Pharmaceutics* 318: 103-117.
56. Mohini Chaurasia, Manish K, Chourasia, Nitin K. Jain et al. (2006). Cross-linked guar gum microspheres; A Viable approach for improved delivery of anticancer drugs for the treatment of colorectal cancer. *AAPS Pharm Sci Tech* 7(3): E1-E9.
57. Mundargi RC, Patil SA, Agnihotri SA et al. (2007) Development of polysaccharide-based colon targeted drug delivery systems for the treatment of ameobiasis. *Drug Dev Ind Pharm* 33(3): 255-264.
58. Munjeri O, Collett JH and Fell JT (1997). Hydrogel beads based on amidated pectins for colon-specific drug delivery: the role of Chitosan in modifying drug release. *Journal of Controlled Release* 46:273-278.
59. Nagpal Deepika, Singh R, Gairola Neha et al. (2006) Mutual azo prodrug of 5-amino salicylic acid for colon targeted drug delivery: Synthesis, Kinetic studies and pharmacological evaluation. *Indian Journal of Pharmaceutical Sciences* 68(2): 171-178.
60. Norihito Shimono, Toshihito Takatori, Masumi Veda et al. (2002) Chitosan dispersed system for the colon-specific drug delivery. *International Journal of Pharmaceutics* 245: 45-54.
61. Norihito Shimono, Toshihito Takatori, Masumi Veda et al. (2003). Multiparticulate chitosan-dispersed system for drug delivery. *Chem.Pharm. Bull* 51 (6): 620-624.

62. Nykanen P, Kragars K, Sakkinen M et al. (1999) Organic acids as excipients in matrix granules for colon-specific drug delivery. *International Journal of Pharmaceutics*. 184: 251-261.
63. Orienti I, Trere R and Zecchi V (2001). Hydrogels formed by cross-linked polyvinyl alcohol as colon- specific drug delivery systems. *Drug development and Industrial Pharmacy* 27(8): 877-884.
64. Paola Mura, Francesca Maestrelli, Marzia cirri et al. (2003) Development of enteric-coated pectin-based matrix tablets for colonic delivery of theophylline. *Journal of Drug Targeting* 11(6): 365-371.
65. Parisa Younessi, Mohammad Reza Avadi, Kooroush Shammi et al. (2004) Preparation and ex vivo evaluation of TEC as an absorption enhancers for poorly absorbable compounds in colon specific drug delivery. *Acta Pharm* 54: 339-345.
66. Samyn C, Kalala.W, Vanden Mooter et al (1995). Synthesis and in vitro biodegradation of poly (ether-ester) azo polymers designed for colon targeting. *International Journal of Pharmaceutics*. 121: 211-216.
67. Sangalli ME, Maronui A, Gazzaniga A et al (2001) In vitro and in vivo evaluation of an oral system for time and/ or site-specific drug delivery. *Journal of Controlled Release* 73:103-110.
68. Sarasija S and Hota A (2000) Colon-specific drug delivery systems. *Indian Journal of Pharmaceutical Sciences* 62(1): 1-8.
69. Semde R, Amighi K, Pierre D, Moes A J et al. (1998) Leaching of pectin from mixed pectin/insoluble polymer films intended for colonic drug delivery. *International Journal of Pharmaceutics*. 174: 233-241.
70. Shinji Sakuma, Zheng-Rong, Jindrich Kopecek et al. (2001) Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin. *Journal of Controlled Release* 75: 365-379.

71. Shweta Arora, Ali J, Alka Ahuja et al. (2006) Pulsatile drug delivery systems: an approach for controlled drug delivery. *Indian Journal of Pharmaceutical Sciences* 68(3): 295-300.
72. Sinha V R and Rachana Kumaria (2001a) Colon drug delivery: prodrug approach. *Pharmaceutical Research* 18(5): 557-564.
73. Sinha V R, Rachana Kumaria (2001b) Polysaccharides in colon-specific drug delivery. *International Journal of Pharmaceutics* 224: 19-38.
74. Sinha V R, Rachana Kumaria (2002) Binders for colon specific drug delivery: an in vitro evaluation. *International Journal of Pharmaceutics* 249: 23-31.
75. Sinha V R, Rachana Kumaria (2003) Microbially triggered drug delivery to the colon. *European Journal of Pharmaceutical Sciences* 18: 3-18.
76. Sinha VR, Bhinge JR, Rachana Kumaria et al. (2006) Development of pulsatile systems for targeted drug delivery of celecoxib for prophylaxis of colorectal cancer *Drug Delivery* 13: 221-225.
77. Sinha VR, Singh A, Singh S et al. (2007) Compression coated systems for colonic delivery of 5-fluorouracil. *J Pharm Pharmacol* 59(3): 359-365.
78. Snezana Milojevic, John Michael Newton, John H Cummings et al (1996). Amylose as a coating for drug delivery to the colon: Preparation and In vitro evaluation using 5-amino salicylic acid pellets. *Journal of Controlled Release* 38: 75-84.
79. Song-Qi Gao, Zheng-Rong Lu, Jindrich Kopecek et al. (2006) Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6 elimination spacer. *Journal of Controlled Release* 110: 323-331.

80. Soodabeh Davaran, Jalal Hanaec, Abbas Khosravi (1999) Release of 5-amino salicylic acid from acrylic type polymeric prodrugs designed for colon-specific drug delivery. *Journal of Controlled Release* 58: 279-287.
81. Sriamornsk P, Nuthanid J, Wan Chana S et al. (2003) Composite film-coated tablets intended for colon – specific delivery of 5-amino salicylic acid: using deesterified pectin. *Pharmaceutical Development and Technology* 8(3): 311-318.
82. Van den Mooter G, Maris B, Samyn C et al. (1997) Use of azo polymers for colon-specific drug delivery. *Journal of Pharmaceutical Sciences* 86(12): 1321-1327.
83. Vincent H. L. Lee, Suman K. Mukergee (2002) Drug delivery-oral colon-specific. In: James Swarbrick and James C. Boylan (ed.) *Encyclopedia of Pharmaceutical Technology*, vol 1, 2nd ed., Marcel Dekker Inc, New York, p. 871-885.
84. Vivek Rajan Sinha, Rachana Kumaria (2003) coating polymers for colon specific drug delivery. A comparative invitro evaluation. *Acta Pharm* 53:41-47.
85. Vyas S.P and Roop K. Khar (ed) (2006) Systems for colon specific drug delivery. In: *Controlled drug delivery concepts and advances*, 1st ed., Delhi, p.218-256.
86. Wei H, Qing D, De-Ying C et al. (2007) Pectin/Ethyl cellulose as film coatings for colon-specific drug delivery: preparation and in vitro evaluation using 5-fluorouracil pellets. *PDA J Pharm Sci Technol* 61(2): 121-130.
87. Wu B, Shun N, Wei X et al. (2007) Characterization of 5-fluorouracil release from hydroxy propyl methyl cellulose compression-coated tablets. *Pharm Dev Technol* 12(2): 203-210.
88. Yunjin Jung, Hak-Hyun Kim, Youngmi Kim et al. (2006) Evaluation of 5-amino salicylyltaurine as a colon-specific prodrug of 5-amino salicylic acid for treatment of experimental colitis. *European Journal of Pharmaceutical Sciences* 28: 26-33.

89. Ziyaur Rahaman, Kanchan Kohli, Roop K.Khar et al. (2006) Characterization of 5-fluorouracil microspheres for colonic delivery. AAPS Pharm Sci Tech 7 (2): E 1-E 9.

Current Author Address:

Sateesh Kumar Vemula*

St.Peter's Institute of Pharmaceutical Sciences.

Warangal Dist.